Tag: Cancer: Prostate
Genomic Classifier Tests Play Heterogeneous Role in Prostate Cancer Risk Classification
Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa
PSMA-PET Provides Additional Risk Stratification in High-Risk Prostate Cancer
M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer
Patient-Centered Pathology Reports Improve Prostate Cancer Understanding
Benefits include better discrimination between risk levels
Prebiopsy MRI Oncologically Safe for Suspected Prostate Cancer
Men with negative mpMRI results avoiding biopsy did not have increased risk for clinically significant prostate cancer
Fish Oil Supplementation Cuts Measure of Prostate Cancer Progression
Findings seen among men enrolled in one year of active surveillance
Prostate Cancer Incidence, Mortality Rates Mainly Stable, Decreasing
Increases seen in some countries, mostly in Africa, Asia, Latin America and the Caribbean, and Central and Eastern Europe
Lasting Reduction in Toxicity Seen for MRI-Guided SBRT for Prostate Cancer
Lower cumulative incidence reported for two-year physician-scored toxicity and late-grade ≥2 toxicity with MRI guidance
Overtreatment of Prostate Cancer Increasing in Men With Short Life Expectancy
From 2000 to 2019, definitive treatment for those with intermediate- or high-risk disease and limited life expectancy increased
Long-Term Complications After Prostate Cancer Treatment Not Uncommon
12-year risk for urinary or sexual complications 7.23 and 2.76 times higher for prostatectomy, radiotherapy versus no treatment
AI Aids Risk Prediction Classification for Prostate Cancer
Authors say this classification has the potential to minimize overtreatment and undertreatment
